-
Strong FY2025 finish: Underlying revenue rose 5.3% to $6.2 billion, adjusted EPS climbed 21% to $1.02, trading margin expanded 160 bps to 19.7%, and free cash flow jumped 52.5% to $840 million helped by a $500 million buyback.
-
Business momentum was led by Orthopedics (Q4 underlying growth 7.9%) driven by hip uptake, CORI robot adoption and improving knees, while Sports Medicine/ENT grew 7.3% with joint repair surpassing $1 billion and Advanced Wound showed mixed results with device strength.
-
2026 guidance targets about 6% organic revenue growth and ~8% trading profit growth; management expects the Integrity Orthopaedics deal (up to $450M) to be marginally dilutive in 2026 but accretive by 2028, while notable headwinds include $60M of tariffs, $20–40M from wound reimbursement changes and China VBP impacts.




